Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Marker Therapeutics Inc (MRKR)

Marker Therapeutics Inc (MRKR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Marker Therapeutics, Inc. Secures $16.1 Million in Private Placement to Advance MT-601 Clinical Study for Lymphoma Treatment Quiver Quantitative, Inc. - Thu Dec 19, 5:24PM CST

Marker Therapeutics secures $16.1 million through private placement to advance MT-601 clinical trials for lymphoma treatment.Quiver AI SummaryMarker Therapeutics, Inc. announced the completion of a $16.1...

MRKR : 3.40 (+0.89%)
Marker Therapeutics Reports Promising Results from Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma Patients Quiver Quantitative, Inc. - Thu Dec 19, 5:24PM CST

The APOLLO study reports positive outcomes for MT-601 in relapsed lymphoma, showing high response rates and good tolerance.Quiver AI SummaryMarker Therapeutics, Inc. provided an update on its Phase 1 APOLLO...

MRKR : 3.40 (+0.89%)
Marker Therapeutics Announces $16.1 Million Private Placement GlobeNewswire - Thu Dec 19, 7:06AM CST

MRKR : 3.40 (+0.89%)
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma GlobeNewswire - Thu Dec 19, 7:05AM CST

MRKR : 3.40 (+0.89%)
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer GlobeNewswire - Tue Dec 17, 6:00AM CST

MRKR : 3.40 (+0.89%)
Marker Therapeutics, Inc. CEO Juan Vera to Present at Ladenburg Thalmann Virtual Symposium on December 12, 2024 Quiver Quantitative, Inc. - Tue Dec 10, 5:54PM CST

Marker Therapeutics CEO Juan Vera will present at the Ladenburg Thalmann Virtual Oncology Symposium on December 12, 2024.Quiver AI SummaryMarker Therapeutics, Inc., a Houston-based clinical-stage immuno-oncology...

MRKR : 3.40 (+0.89%)
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium GlobeNewswire - Tue Dec 10, 7:30AM CST

MRKR : 3.40 (+0.89%)
Marker Therapeutics, Inc. CEO Juan Vera to Present at Citizens JMP Hematology and Oncology Summit on December 2, 2024 Quiver Quantitative, Inc. - Tue Nov 26, 8:16PM CST

Marker Therapeutics CEO Juan Vera will present company updates at the Citizens JMP Hematology and Oncology Summit on December 2, 2024.Quiver AI SummaryMarker Therapeutics, Inc. announced that its President...

MRKR : 3.40 (+0.89%)
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit GlobeNewswire - Tue Nov 26, 10:00AM CST

MRKR : 3.40 (+0.89%)
Marker Therapeutics, Inc. Reports Third Quarter 2024 Financial Results and Progress on Clinical Trials Quiver Quantitative, Inc. - Fri Nov 15, 1:52AM CST

Marker Therapeutics reports Q3 2024 financial results, highlighting progress in clinical trials and $4 million in NIH grants.Quiver AI SummaryMarker Therapeutics, Inc. announced corporate updates and financial...

MRKR : 3.40 (+0.89%)

Barchart Exclusives

Is Rumble Stock a Buy, Sell, or Hold After a $775 Million Investment? Barchart - 1 hour ago
Rumble’s stock has shot up following an investment agreement with a giant crypto firm. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot